Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

OBJECTIVE: To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and KRAS mutations in these patients. METHODS: This was a single-center, randomized, open-label, prospective trial. Eight...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Wang, Jack P., Wu, Chen-Yi, Yeh, Yi-Cheng, Shyr, Yi-Ming, Wu, Ying-Ying, Kuo, Chen-Yu, Hung, Yi-Ping, Chen, Ming-Huang, Lee, Wei-Ping, Luo, Jiing-Chyuan, Chao, Yee, Li, Chung-Pin
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Clinical Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627242/
https://ncbi.nlm.nih.gov/pubmed/26046796
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы